Table 1. Clinical pipeline of biologic and drug wound therapies.

RNAi, RNA interference.

Phase	Clinical trial (NCT)	Company	Mode of action	Indication
1	NCT04803708	Technophage	Biologic: Antibacterial bacteriophage dispersion	Diabetic foot ulcer; infections with P. aeruginosa, S. aureus, Acinetobacter
	NCT04281992	Aurealis Pharma	Biologic: Genetically engineered L. lactis bacteria expressing anti-inflammatory, angiogenic, and tissue-repairing proteins	Diabetic foot ulcer
	NCT03569267	OLX101	Biologic: CTGF RNAi therapeutics stem cell therapy	Cicatrix, hypertrophic
	NCT02590042	ADSC-SVF-002	Biologic: Wound healing agent	Abnormally healing wounds, scars, soft tissue defects
	NCT03695939	XenoTherapeutics	Biologic: Live cell xenotransplantation skin product derived from genetically engineered (alpha-1,3-galactosyltransferase knockout) porcine donors	Deep full-thickness burn injury (disorder)
	NCT04890574	RenovaCare	Biologic: Autologous stem cells obtained from donor skin using CellMist System and sprayed on wound with SkinGun device	Burns, burns second degree, burns deep second degree
2	NCT04817228	Mediwound	Drug: Debridement by protease-containing wound solutions	Venous leg ulcer, diabetic foot ulcer
	NCT01898923	Oneness Biotech	Drug: Plant extract for M2 polarization	Diabetic foot
	NCT02664740	Pherecydes	Drug: Topical anti-staphylococcal bacteriophage cocktail against methicillin-resistant or susceptible S. aureus	Diabetic foot, staphylococcal infections
	NCT03880058	Pharma SLI-F06	Drug: Anti-scarring agents (FMOD peptide)	Scars
	NCT04331080	Granexin	Drug: Cx43 mimetics	Mammoplasty, scarring, scar, breast reconstruction
	NCT01655407	ESS	Drug: Collagen/fibroblast	Thermal injury, deep partial-thickness, burn, full-thickness burn
	NCT02116010	Phagoburn	Drug: Bacteriophage	Wound infection
3	NCT03282981	VA Office of Research and Development	Drug: Pro-angiogenic timolol hydrogel	Chronic diabetic foot ulcers, diabetic neuropathic ulcers, nonhealing wound